June 15–16, 2020 | 11:00AM–3:30PM ET | 3:00–7:30PM UTC | 5:00–9:30PM CEST*
*Program is subject to change
As the world faces the greatest global pandemic of our lifetimes, the critical importance of vaccine development has come to the forefront of scientific and public audiences alike. Over the course of history, vaccination has enabled us to conquer devastating diseases from measles to smallpox, but new challenges arise when addressing an emerging pandemic in real time. This virtual meeting will assemble the world’s leading vaccinology and global health experts to present the latest advances in vaccine design and development. Finally, this virtual conference will discuss how to best apply these strategies in the context of the current pandemic.
The field of vaccinology has made great leaps in recent years, providing novel technologies and approaches that can be leveraged to our advantage against the novel coronavirus, COVID-19. Incredible advances in science and technology now make it technically possible to develop vaccines against many new targets. Meanwhile, innovative approaches to vaccine development are tackling challenges of emerging infections and implementation in low-income countries. These advances, among many others, will guide the way towards a safe and effective COVID-19 vaccine. Additionally, these new scientific advances will set the stage for success against this pandemic, as vaccinologists race against the ever-rising global death toll.
This virtual meeting program will cover many important facets of vaccine science, technology and strategy, including:
Program is intended for scientific researchers and clinical audiences.
Join us for this landmark virtual event, brought to you by Keystone Symposia.
Regular Registration Rate: $50 USD
#VKSvaxcovid19
Graduate students, postdoctoral fellows and early stage investigators, as well as life scientists from low- to middle- income countries (all career stages), are eligible to request a free registration code.
Keynote Speaker
Galit Alter
MIT and Harvard University
Yasmine Belkaid
NIAID, National Institutes of Health
Anthony S. Fauci
NIAID, National Institutes of Health
George Fu Gao
Chinese Academy of Sciences
Barney S. Graham
NIAID, National Institutes of Health
Richard Hatchett
Coalition for Epidemic Preparedness Innovations, CEPI
Neil P. King
University of Washington
Antonio Lanzavecchia
Institute for Research in Biomedicine
Ulrike Protzer
Technische Universität München
Bali Pulendran
Stanford University School of Medicine
Rino Rappuoli
GlaxoSmithKline Vaccines
Federica Sallusto
Università della Svizzera Italiana & ETH Zurich
Robert A. Seder
NIAID, National Institutes of Health
Robin Shattock
Imperial College London
Lynda M. Stuart
Bill & Melinda Gates Foundation
Christine Shaw
Moderna
Gabriel D. Victora
Rockefeller University
Hedda Wardemann
German Cancer Research Center
Catherine J. Wu
Dana-Farber Cancer Institute
Funding for this conference was made possible (in part) by 1R13AI150086-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.